Conv. Plasma
Nigella Sativa

All remdesivir studies
Meta analysis
study COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -76% Improvement Relative Risk Ventilation -112% Remdesivir  Mahajan et al.  LATE TREATMENT  RCT Is late treatment with remdesivir beneficial for COVID-19? RCT 70 patients in India (June - December 2020) Higher mortality (p=0.47) and ventilation (p=0.42), not sig. Mahajan et al., Indian J. Anasthesia, Mar 2021 Favors remdesivir Favors control

Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study

Mahajan et al., Indian Journal of Anasthesia, doi:10.4103/ija.IJA_149_21
Mar 2021  
  Source   PDF   All   Meta
Small RCT with 34 remdesivir patients and 36 controls finding no significant difference in clinical outcomes.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 76.5% higher, RR 1.76, p = 0.47, treatment 5 of 34 (14.7%), control 3 of 36 (8.3%).
risk of mechanical ventilation, 111.8% higher, RR 2.12, p = 0.42, treatment 4 of 34 (11.8%), control 2 of 36 (5.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mahajan et al., 20 Mar 2021, Randomized Controlled Trial, India, peer-reviewed, 3 authors, study period June 2020 - December 2020, average treatment delay 6.84 days.
This PaperRemdesivirAll
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
Dr Lakshmi Mahajan, Gifty A P Singh, Gifty
Indian Journal of Anaesthesia, doi:10.4103/ija.ija_149_21
Background and Aims: When the world was frantically searching for a drug effective against the coronavirus disease (COVID)-19, remdesivir, a broad-spectrum anti-viral medication, became a part of the COVID treatment. We planned a study to evaluate improvement in clinical outcomes with remdesivir treatment for five days. Methods: Participants more than 40-years old and with moderate to severe COVID-19 but not on mechanical ventilation were randomly assigned into two groups-remdesivir group (34 cases) to receive the study drug intravenous (IV) remdesivir for five days plus the standard care (SC) and non-remdesivir group (36 cases) to receive the SC but not to receive the study drug. Follow-up was continued for 12 days after the beginning of treatment or until discharge/death. Patient's clinical status was assessed by laboratory investigations and physical examination (from day 1 to day 12 on a 4-point ordinal scale and from day 12 to 24 on a 6-point ordinal scale). Oxygen support requirements and adverse events were recorded. The data were entered and analysed using Statistical Package for the Social Sciences (SPSS) version 22.0. Results: High-flow oxygen support and non-invasive ventilation was required at baseline by lesser patients in the remdesivir group. In the end, both groups had similar outcomes after adjustment for baseline clinical status. There was no statistical difference in mortality between the two groups (p = 0.749). Patients in both groups had an equal time to recovery. There was no difference in the occurrence of adverse effects of remdesivir between the two groups. Conclusion: Remdesivir therapy for five days did not produce improvement in clinical outcomes in moderate to severe COVID-19 cases.
Conflicts of interest There are no conflicts of interest.
Bajwa, Editing from the dungeons of the pandemic; An editor's agonisingly painful battle with COVID-19, Indian J Anaesth
Bajwa, Sarna, Bawa, Mehdiratta, Peri-operative and critical care concerns in corona virus pandemic, Indian J Anaesth
Biegel, Tomashek, Lori, Mehta, Barry et al., Remdesivir for the treatment of Covid -19 -Final Report, N Engl J Med
Fauci, Lane, Field Rr, Covid-19 -Navigating the uncharted, N Engl J Med
Goldman, David, Hui, Marks, Bruno et al., Remdesivir for 5 or 10 days in patients with severe Covid -19, N Engl J Med
Mulangu, Dodd, Jr, Mbaya, Proschan et al., A randomized, controlled trial of Ebola virus disease therapeutics, N Engl J Med
O'keeffe, Ambler, Barber, Sample size calculations based on a difference in medians for positively skewed outcomes in health care studies, BMC Med Res Methodol, doi:10.1186/s12874-017-0426-1
Spinner, Gottlieb, Criner, Lopez, Cattelan et al., Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial, JAMA
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Zhang, Guanhua, Ronghui, Zhao et al., Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicenter trial, Lancet
Williamson, Feldmann, Schwarz, Meade-White, Porter et al., Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2, bioRxiv, doi:10.1101/2020.04.15.043166
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop